These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: HER2/neu negative salivary duct carcinoma of parotid: A case with forty months recurrence free follow up.
    Author: Gokavarapu S, Fonseca D, Puthamakula S, Reddy BP, Reddy BS, Murthy S.
    Journal: Int J Surg Case Rep; 2015; 8C():22-4. PubMed ID: 25603487.
    Abstract:
    INTRODUCTION: Salivary duct carcinoma (SDC) is very rare, only 1-3% of all salivary gland tumors are reported as SDC. SDC predominantly occurs in elderly males, SCD is characterized by an aggressive clinical course of the disease with less than 60% five years survival from the day of initial diagnosis, lymph node metastasis and facial nerve involvement is common, the current literature lacks protocol regarding management of this entity and the advantage of adjuvant therapy has not been evaluated due to its rare occurrence. PRESENTATION OF CASE: We report patient with stage IV HER2/neu negative SDC successfully treated with surgery followed by adjuvant radiotherapy, patient is followed up for 40 months without evidence of recurrence or metastasis. DISCUSSION: SDC is reported to be similar to mammary duct carcinoma in clinical and immunohistologic typing, further it shows an association of expression of HER-2/neu and p53, with early local disease recurrence, distant metastasis and survival, however; current case was adequately followed up and reevaluated after 26 months, MRI did not show evidence of recurrence. CONCLUSION: SDC is a rare tumor and information on association of HER2/neu with survival is useful in further research on this tumor.
    [Abstract] [Full Text] [Related] [New Search]